Site icon OncologyTube

Galeterone and alternative splicing does this agent differ from approved agents such as abiraterone and enzalutamide

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses galeterone and alternative splicing does this agent differ from approved agents such as abiraterone and enzalutamide at ASCO GU 2016 in San francisco.

Exit mobile version